Antares Pharma


Phase 3 clinical trials for sex dysfunction gel fall short

A gel developed by Antares (AMEX:AIS) and licensed to BioSante Pharmaceuticals (NASDAQ:BPAX) to treat female sexual dysfunction failed two phase 3 clinical trials testing efficacy, according to a statement from BioSante. Initial analysis of the data from the trials showed that the tests “did not meet the co-primary or secondary endpoints,” the statement said. LibiGel […]